Moreover, in frail patients with type 2 diabetes on insulin (but not in those on sulfonylureas), a relationship between cancer and severe hypoglycemic events has been shown, alluding to a specific multimorbid patient phenotype that needs to be recognized, as it poses challenging management issues, including de-intensification of glucose-lowering therapies [60,61,62]. Here, INS is linked to cancer.